FDA Should Oversee Clinical Trial Disclosure, New York AG Spitzer Says

FDA should take the lead in defining rules for clinical trial reporting to eliminate the issue of "publication bias," New York Attorney General Eliot Spitzer said during a recent appearance at the Chautauqua Institution in New York